refludan
celgene europe ltd. - lepirudin - thromboembolism; thrombocytopenia - antithrombotic agents - anticoagulation in adult patients with heparin-induced thrombocytopenia type ii and thromboembolic disease mandating parenteral antithrombotic therapy.the diagnosis should be confirmed by the heparin-induced platelet activation assay or an equivalent test.
bivalirudin cipla 250 milligram pdr/conc/soln/inj/inf
cipla (eu) limited - bivalirudin - pdr/conc/soln/inj/inf - 250 milligram - direct thrombin inhibitors
angiox
the medicines company uk ltd - bivalirudin - acute coronary syndrome - antithrombotic agents - angiox is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (pci), including patients with st-segment-elevation myocardial infarction (stemi) undergoing primary pci.angiox is also indicated for the treatment of adult patients with unstable angina / non-st-segment-elevation myocardial infarction (ua / nstemi) planned for urgent or early intervention.angiox should be administered with aspirin and clopidogrel.
revasc
canyon pharmaceuticals ltd. - desirudin - venous thrombosis - antithrombotic agents - prevention of deep venous thrombosis in patients undergoing elective hip or knee replacement surgery.
colestipol hydrochloride tablet
greenstone llc - colestipol hydrochloride (unii: x7d10k905g) (colestipol - unii:k50n755924) - colestipol hydrochloride 1 g - since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and ldl-c in patients with primary hypercholesterolemia (elevated ldl-c) who do not respond adequately to diet. generally, colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy (see ncep guidelines). a minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. shorter periods may be considere
peter island sunscreen spf 30- homosalate, oxybenzone, octisalate, avobenzone, octocrylene lotion
amway corp. -
angiox 250mg powder for concentrate for solution for infusion vials
the medicines company uk ltd - bivalirudin - powder for solution for infusion - 250mg
bivalirudin 250mg powder for concentrate for solution for infusion vials
accord-uk ltd - bivalirudin - powder for solution for infusion - 250mg
pradaxa 75
boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 75 mg - dabigatran etexilate - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
pradaxa 110
boehringer ingelheim israel ltd. - dabigatran etexilate as mesilate - capsules - dabigatran etexilate as mesilate 110 mg - dabigatran etexilate - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.